AMGN · earnings call history
Amgen Q1 FY26 — springboard year on track as growth drivers offset biosimilar erosion, guidance raised
Read the briefAmgen Q4 FY25 — Strong Portfolio Performance and Pipeline Momentum
Read the briefAmgen Q3 FY25 — Strong Volume Growth and Pipeline Momentum
Read the briefAmgen Q4 FY24 — Strong Product Sales Growth and Pipeline Advancement
Read the briefBrowse all US companies on the earnings-call register.